Income StatementBalance SheetCash FlowSegments
Cardinal Health logo

Cardinal Health Business Segments

Business, geographic, and product segment breakdowns

Cardinal Health generates $250.74B in annual revenue across 3 key segments: Cost of product sold ($12.8B), Other Segments ($6.7B), and Pharmaceutical and Specialty Solutions ($231.36B). The company-wide operating margin is 0.92%. Based on the Q1 2026 filing.

Cost of product sold (TTM)$12.8BOther Segments (TTM)$6.7BPharmaceutical and Specialty Solutions (TTM)$231.36B
Latest FilingQ1 2026
Report Date2026-04-30
Market Cap$43.6B
P/E Ratio28.07
ROE-53.81%

Products & Services

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Distribution, selling, general, and administrative expenses$227.3M$227.3M$227.3M———

Geographic

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
PP&E (Net)——$436.0M$435.0M$432.0M$434.0M
Revenue$428.0M$399.0M$434.0M$419.0M$435.0M$423.0M

Business Segments

Cost of products sold

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Pharmaceutical and Specialty Solutions$49.8B$49.2B$54.2B$57.9B$59.2B$54.6B
Cost of product sold$2.6B$2.6B$2.6B$2.6B$2.7B$2.6B
Other Segments$969.0M$975.0M$1.2B$1.2B$1.3B$1.3B

Costs and Expenses

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Pharmaceutical and Specialty Solutions$50.3B$49.8B$54.8B$58.5B$60.0B$55.3B
Cost of product sold$3.1B$3.1B$3.1B$3.1B$3.2B$3.1B
Other Segments$1.2B$1.2B$1.4B$1.5B$1.5B$1.5B

D&A

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Pharmaceutical and Specialty Solutions$46.0M$44.0M$68.0M$61.0M$64.0M$70.0M
Cost of product sold$60.0M$56.0M$47.0M$55.0M$55.0M$54.0M
Other Segments$40.0M$31.0M$0.0$29.0M$30.0M$26.0M

Distribution, selling, general and administrative expenses

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Pharmaceutical and Specialty Solutions$568.0M$604.0M$664.0M$681.0M$739.0M$732.0M
Cost of product sold$512.0M$487.0M$521.0M$505.0M$502.0M$518.0M
Other Segments$196.0M$195.0M$254.0M$254.0M$254.0M$259.0M

Goodwill

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Pharmaceutical and Specialty Solutions$4.3B$7.7B$7.9B$8.0B$9.9B$9.7B
Other Segments$1.2B$1.2B$1.7B$1.7B$1.7B$1.7B
Cost of product sold$0.0$0.0$0.0$0.0$0.0$0.0

Goodwill, Acquired During Period

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Pharmaceutical and Specialty Solutions$763.0M$3.4B$208.0M$21.0M$1.9B-$9.0M
Other Segments$0.0$0.0$578.0M-$3.0M$3.0M-$1.0M
Cost of product sold$0.0$0.0$0.0$0.0$0.0$0.0

Goodwill, Impairment Loss

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Pharmaceutical and Specialty Solutions—————$184.0M

Revenue

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Pharmaceutical and Specialty Solutions$50.8B$50.4B$55.4B$59.2B$60.7B$56.1B
Cost of product sold$3.2B$3.2B$3.2B$3.2B$3.3B$3.1B
Other Segments$1.3B$1.3B$1.6B$1.6B$1.7B$1.7B

Segment Reporting, Long-Lived Asset, Expenditure for Addition

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Pharmaceutical and Specialty Solutions$12.0M$33.0M$62.0M$32.0M$23.0M$37.0M
Cost of product sold$21.0M$28.0M$61.0M$19.0M$23.0M$32.0M
Other Segments$22.0M$18.0M$36.0M$15.0M$23.0M$25.0M

Total Assets

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Pharmaceutical and Specialty Solutions$32.1B$35.7B$37.3B$38.7B$43.4B$41.0B
Cost of product sold$7.1B$7.2B$6.9B$7.1B$7.0B$6.9B
Other Segments$2.7B$2.7B$4.0B$4.0B$4.1B$4.1B

Total operating earnings

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Pharmaceutical and Specialty Solutions$531.0M$662.0M$535.0M$667.0M$687.0M$784.0M
Other Segments$118.0M$134.0M$160.0M$166.0M$179.0M$179.0M
Cost of product sold$18.0M$39.0M$70.0M$46.0M$37.0M$25.0M

Accumulated goodwill impairment loss

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Other Operating Segment——$829.0M———

Number of operating segments

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Other Segments0.000.000.003.000.000.00

Percent of Gross Trade Receivables

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Pharmaceutical and Specialty Solutions——26.0%———